Details of the Drug

General Information of Drug (ID: DM5FLTY)

Drug Name

Risedronate

Synonyms

Risedronic acid; 105462-24-6; Actonel; Atelvia; Acido risedronico; Acidum risedronicum; Benet; Risedronic acid [INN:BAN]; Acidum risedronicum [INN-Latin]; Acido risedronico [INN-Spanish]; Acide risedronique [INN-French]; Risedronic acid monohydrate; NE-58095; UNII-KM2Z91756Z; C7H11NO7P2; NE 58019; HSDB 7326; [1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl]phosphonic acid; (1-hydroxy-1-phosphono-2-pyridin-3-yl-ethyl)phosphonic acid; Risedronic acid (Actonel); CHEMBL923; CHEBI:8869; Phosphonic acid,; Benet; RIS; Ridron; Acide risedronique; Bisphosphonate 1; Actonel (TN); Ridron (TN); Risedronic acid (INN); (1-Hydroxy-2-(3-pyridyl)ethylidene)diphosphonic acid; (1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonic acid; (1-hydroxy-2-pyridin-3-ylethane-1,1-diyl)bis(phosphonic acid); 1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE BIS-PHOSPHONIC ACID

Indication

Disease Entry	ICD 11	Status	REF
Bone Paget disease	N.A.	Approved	[1]
Osteoporosis	FB83.0	Approved	[1]
Paget's disease	FB85	Approved	[2]
------------------------------------------------------------------------------------

Therapeutic Class

Bone Density Conservation Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

283.11

Logarithm of the Partition Coefficient (xlogp)

-3.1

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 20-40 min []
Clearance: The renal clearance of drug is 52 mL/min []
Half-life: The concentration or amount of drug in body reduced by one-half in 1.5 hours [3]
Metabolism: The drug is not metabolised [4]
Vd: The volume of distribution (Vd) of drug is 13.8 L/kg []

Chemical Identifiers

Formula: C7H11NO7P2
IUPAC Name: (1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonic acid
Canonical SMILES: C1=CC(=CN=C1)CC(O)(P(=O)(O)O)P(=O)(O)O
InChI: InChI=1S/C7H11NO7P2/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15)
InChIKey: IIDJRNMFWXDHID-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 5245
ChEBI ID: CHEBI:8869
CAS Number: 105462-24-6
DrugBank ID: DB00884
TTD ID: D0PA5S
ACDINA ID: D00598

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Geranyltranstransferase (FDPS)	TTIKWV4	FPPS_HUMAN	Inhibitor	[5]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Mitogen-activated protein kinase 1 (MAPK1)	OTH85PI5	MK01_HUMAN	Post-Translational Modifications	[6]
Mitogen-activated protein kinase 3 (MAPK3)	OTCYKGKO	MK03_HUMAN	Post-Translational Modifications	[6]
Ras-related protein Rab-6A (RAB6A)	OTLS86J5	RAB6A_HUMAN	Post-Translational Modifications	[7]
Ras-related protein Rap-1A (RAP1A)	OT5RH6TI	RAP1A_HUMAN	Post-Translational Modifications	[8]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Risedronate (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Framycetin	DMF8DNE	Moderate	Increased risk of hypocalcemia by the combination of Risedronate and Framycetin.	Alcoholic liver disease [DB94]	[9]
Kanamycin	DM2DMPO	Moderate	Increased risk of hypocalcemia by the combination of Risedronate and Kanamycin.	Bacterial infection [1A00-1C4Z]	[9]
Streptomycin	DME1LQN	Moderate	Increased risk of hypocalcemia by the combination of Risedronate and Streptomycin.	Bacterial infection [1A00-1C4Z]	[9]
Netilmicin	DMRD1QK	Moderate	Increased risk of hypocalcemia by the combination of Risedronate and Netilmicin.	Bacterial infection [1A00-1C4Z]	[9]
Ketoprofen	DMRKXPT	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Risedronate and Ketoprofen.	Chronic pain [MG30]	[10]
Ethacrynic acid	DM60QMR	Moderate	Increased risk of hypocalcemia by the combination of Risedronate and Ethacrynic acid.	Essential hypertension [BA00]	[11]
Bumetanide	DMRV7H0	Moderate	Increased risk of hypocalcemia by the combination of Risedronate and Bumetanide.	Heart failure [BD10-BD1Z]	[11]
Didanosine	DMI2QPE	Moderate	Decreased absorption of Risedronate due to formation of complexes caused by Didanosine.	Human immunodeficiency virus disease [1C60-1C62]	[12]
Etelcalcetide	DMHP9BL	Major	Increased risk of hypocalcemia by the combination of Risedronate and Etelcalcetide.	Hyper-parathyroidism [5A51]	[13]
Meclofenamic acid	DM05FXR	Moderate	Increased risk of nephrotoxicity by the combination of Risedronate and Meclofenamic acid.	Inflammatory spondyloarthritis [FA92]	[10]
Iron	DMAP8MV	Moderate	Decreased absorption of Risedronate due to formation of complexes caused by Iron.	Iron deficiency anaemia [3A00]	[12]
Exjade	DMHPRWG	Major	Increased risk of GI mucosal injury/bleeding risk by the combination of Risedronate and Exjade.	Mineral absorption/transport disorder [5C64]	[14]
Lanthanum carbonate	DMMJQSH	Moderate	Decreased absorption of Risedronate due to formation of complexes caused by Lanthanum carbonate.	Mineral absorption/transport disorder [5C64]	[15]
Aspirin	DM672AH	Moderate	Increased risk of nephrotoxicity by the combination of Risedronate and Aspirin.	Pain [MG30-MG3Z]	[10]
Ibuprofen	DM8VCBE	Moderate	Increased risk of nephrotoxicity by the combination of Risedronate and Ibuprofen.	Pain [MG30-MG3Z]	[10]
Choline salicylate	DM8P137	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Risedronate and Choline salicylate.	Postoperative inflammation [1A00-CA43]	[10]
Bromfenac	DMKB79O	Moderate	Increased risk of nephrotoxicity by the combination of Risedronate and Bromfenac.	Postoperative inflammation [1A00-CA43]	[10]
Salsalate	DM13P4C	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Risedronate and Salsalate.	Rheumatoid arthritis [FA20]	[10]
Oxaprozin	DM9UB0P	Moderate	Increased risk of nephrotoxicity by the combination of Risedronate and Oxaprozin.	Rheumatoid arthritis [FA20]	[10]
Salicyclic acid	DM2F8XZ	Moderate	Increased risk of nephrotoxicity by the combination of Risedronate and Salicyclic acid.	Seborrhoeic dermatitis [EA81]	[10]
Plazomicin	DMKMBES	Moderate	Increased risk of hypocalcemia by the combination of Risedronate and Plazomicin.	Urinary tract infection [GC08]	[9]
-----------


⏷ Show the Full List of 21 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
FD&C blue no. 2	E00446	2723854	Colorant
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS	E00309	24671	Colorant
Sodium stearyl fumarate	E00545	23665634	lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Crospovidone	E00626	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium phosphate monobasic monohydrate	E00428	516949	Buffering agent; Complexing agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
--------------------


⏷ Show the Full List of 21 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Risedronic acid 5 mg tablet	5 mg	Oral Tablet	Oral
Risedronic acid 150 mg tablet	150 mg	Oral Tablet	Oral
Risedronic acid 30 mg tablet	30 mg	Oral Tablet	Oral
Risedronic acid 35 mg tablet	35 mg	Oral Tablet	Oral
Risedronic acid 75 mg tablet	75 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Risedronate FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3176).
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	Ghannoum M, Arendrup MC, Chaturvedi VP, Lockhart SR, McCormick TS, Chaturvedi S, Berkow EL, Juneja D, Tarai B, Azie N, Angulo D, Walsh TJ: Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections. Antibiotics (Basel). 2020 Aug 25;9(9). pii: antibiotics9090539. doi: 10.3390/antibiotics9090539.
5	Activity of bisphosphonates against Trypanosoma brucei rhodesiense. J Med Chem. 2002 Jul 4;45(14):2904-14.
6	Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines. Anticancer Res. 2008 Jul-Aug;28(4B):2147-54.
7	Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cells. Int J Cancer. 2006 Sep 15;119(6):1254-61. doi: 10.1002/ijc.21977.
8	Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity. Bone. 2001 Oct;29(4):336-43. doi: 10.1016/s8756-3282(01)00589-0.
9	Chang JT, Green L, Beitz J "Renal failure with the use of zoledronic acid." N Engl J Med 349 (2003): 1676-9 discussion 1676-9. [PMID: 14573746]
10	Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
11	Product Information. Skelid (tilundronate). Sanofi Winthrop Pharmaceuticals, New York, NY.
12	Product Information. Bonefos (clodronate). Rhone-Poulenc Rorer Canada Inc, Laval, QC.
13	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
14	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
15	Canadian Pharmacists Association.